Trial Profile
Left ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Aortic valve stenosis; Atrial fibrillation
- Focus Pharmacodynamics
- 01 Sep 2010 Results published in the American Journal of Cardiology.
- 01 Sep 2010 Status changed from active, no longer recruiting to completed, based on an article published in the American Journal of Cardiology.
- 01 Sep 2010 Primary endpoint 'Left ventricular muscle mass index' has been met, according to an article published in the American Journal of Cardiology.